Reversal Agents

About

  • Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.

    Load more

    Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.

    Anticoagulant reversal should only be considered with life-threatening bleeds, with bleeds that fail to respond to usual measures, and in patients requiring urgent surgery.

    Idarucizumab is licensed for dabigatran reversal. The Factor Xa inhibitor andexanet alfa has recently been licensed in the US for reversal of rivaroxaban, apixaban and edoxaban.

    Load Less

Videos

Reversal Agents - New This Month

Reversal Agents - Idarucizumab for Dabigatran Reversal

Reversal Agents - Andexanet Alfa for Factor Xa Inhibitors

Reversal Agents - Ciraparantag for Factor Xa Inhibitors

Reversal Agents - Guidelines/expert recommendations

Subscribe to Reversal Agents